Myeloproliferative Neoplasms News

THOROFARE, NJ — Healio is set to host the inaugural hematology/oncology Disruptive Innovators Award Reception during the American Society of Clinical Oncology Annual Meeting. The event will take place on June 4, 2022, at the Hyatt Regency McCormick Place in Chicago, Illinois.

SALT LAKE CITY — Socioeconomic disadvantage among hematopoietic stem cell transplant donors appeared associated with poorer outcomes among transplant recipients, according to study results.

SALT LAKE CITY — Early azithromycin use did not affect hematologic relapse among pediatric hematopoietic stem cell transplant recipients, according to study results.

SALT LAKE CITY — Treosulfan plus fludarabine conditioning after allogeneic hematopoietic stem cell transplantation conferred better outcomes for patients with myelodysplastic syndrome than a busulfan-based regimen, study results showed.

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

As important as the care of Ukrainian citizens with cancer is to clinicians in that country, this priority has been overshadowed by more immediate concerns.

Just as physicians became accustomed to wearing pagers 40 years ago or being tied to smartphones 2 decades ago, many have become active on social media as it entered their practices.

An important component of cancer care is communication with patients and caregivers about their disease.

Most cancer drug approvals between 2016 and 2021 applied to second-, third- or later-line treatment settings and did not displace current standard-of-care therapies, according to a study published in JAMA Network Open.

The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.